GO
Loading...

Pharmaceuticals

More

  • One-on-One with Schering-Plough CEO Fred Hassan Wednesday, 13 Feb 2008 | 11:05 AM ET

    In a CNBC and Mad Money exclusive, Cramer sat down with Schering-Plough CEO Fred Hassan for his first interview since the controversy over the effectiveness of the cholesterol drug Vytorin. Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Genentech's Avastin Study: Will It Help Get FDA Approval? Wednesday, 13 Feb 2008 | 10:29 AM ET

    After the closing bell yesterday Genentech popped out a stock-moving press release. The world's most highly-valued biotech announced that its drug Avastin when used in combo with Sanofi-Aventis' chemo drug, Taxotere, helped women with a certain type of aggressive, advanced breast cancer live longer without the disease getting worse.

  • Fujifilm Launches $1.45 Billion Bid for Toyama Chemical Wednesday, 13 Feb 2008 | 1:13 AM ET

    Digital camera and medical equipment maker Fujifilm Holdings said on Wednesday it will spend up to 155 billion yen ($1.45 billion) to take control of drug maker Toyama Chemical to grow in the pharmaceuticals market.

  • The current issue (February 18, 2008) of New York Magazine has a story that it teases on the cover above the masthead, "No Smoking Wonder Drug." Below it in drug-label fine print the sub-head is: "Makes quitter talk to potted plants."

  • Euro Stocks Rally, Financials Gain Tuesday, 12 Feb 2008 | 12:40 PM ET

    European stocks closed sharply higher Tuesday, after U.S. billionaire investor Warren Buffett inspired a late rally by offering to take on $800 billion worth of debt insured by top bond insurers.

  • Schering-Plough is bringing up the rear of big pharma earnings season this morning--it reported later than normal because it apparently took longer to do all the accounting for a big acquisition--with a beat on the top and bottom line. But investors, as is usually the case, are more concerned about guidance.

  • Schering-Plough's Loss Is Narrower than Expected Tuesday, 12 Feb 2008 | 7:55 AM ET

    Schering-Plough Tuesday reported a quarterly loss as special charges from its acquisition of Organon Biosciences late last year offset sharply higher sales, but results beat Wall Street expectations.

  • Dendreon/Provenge Petition: It Ain't Me On There Monday, 11 Feb 2008 | 12:39 PM ET

    Anyone who has followed the Dendreon/Provenge saga knows there are a lot of passionate people attached to it. And apparently one of them may go by the name Mike Huckman. Last night it was brought to my attention that my name appears (or appeared) on line 277 of this online petition.

  • Allergan "Suffering" From Adverse Botox Events Friday, 8 Feb 2008 | 4:46 PM ET

    Shares of Allergan are taking a big hit today after the Food and Drug Administration announced it's putting out an "Early Communication" (Translation: We're reviewing some reports of adverse events, but in the meantime, doctors and patients should be vigilant) regarding potentially fatal side effects of the popular muscle relaxant Botox.

  • In their stump speeches and debates, Hillary Clinton and Barack Obama often talk about pushing back against the Washington influence of the powerful pharmaceutical lobby and keeping drug company profits in check.

  • Glaxo Profit Falls on Sliding Diabetes Drug Sales Thursday, 7 Feb 2008 | 12:57 PM ET
    Glaxo Smith Kline

    GlaxoSmithKline forecast lower 2008 earnings due to falling sales of diabetes drug Avandia and increased generic competition, sending shares in Europe's biggest drugmaker down 7.6 percent on Thursday.

  • Glaxo's Avandia Hits The Bottom Line--Hard Thursday, 7 Feb 2008 | 12:43 PM ET

    Shares of GlaxoSmithKline this morning are getting hammered because the company announced it expects earnings per share to fall by a mid-single digit percentage this year. Analysts thought they'd grow by three percent.

  • Diabetes Drug Safety: Has Another Red Flag Been Raised? Wednesday, 6 Feb 2008 | 3:07 PM ET

    Reaction to part of a big government-sponsored diabetes drug study being halted over fatalities is pouring in from several corners. The American Diabetes Association put out a press release saying it "strongly encourages people with diabetes not to alter their course of treatment without first consulting with their health care team...

  • Biogen Idec Draws "Line In The Sand" With Carl Icahn Wednesday, 6 Feb 2008 | 11:28 AM ET

    I'm blogging a little later than usual because I got sidetracked by the breaking news on the government stopping part of a big diabetes drug study over safety concerns--more people died in a group that was being intensively treated to get their blood sugar levels below current recommendations.

  • Bloodthinner Plavix Gets Big Boost in New  Study Tuesday, 5 Feb 2008 | 4:37 PM ET

    Heart patients with drug-coated stents who stop taking the popular bloodthinner Plavix are quickly put at a higher risk of death, according to a new study published in the "Journal of the American Medical Association."

  • Drug Stocks: Real Downers And At A Two-Year Low Tuesday, 5 Feb 2008 | 4:29 PM ET

    Yes, it was a big down day for equities, but I wanted to call attention to the fact that according to one of our resident stock gurus, Robert Hum, the Amex Pharmaceutical Index (you can see the 15 stocks that make up the so-called DRG here) closed at a two-year low today.

  • Boston Scientific And The "Struggling" Stents Tuesday, 5 Feb 2008 | 10:25 AM ET

    Sales of drug-coated stents, Boston Scientific's most profitable products, came in at the low end of the company's guidance in the fourth quarter. Stents are the fragile little wire mesh cylinders that act like scaffolding to prop open clogged arteries.

  • FDA At Level "Orange" Safety Warning? Monday, 4 Feb 2008 | 2:14 PM ET

    The Food and Drug Administration continues to get a lot of attention and scrutiny. In an editorial over the weekend "The New York Times" wrote, "The F.D.A. desperately needs an infusion of money and talent." Then, "USA Today" today is running a front-page article on something I recently blogged about and other reporters tackled a few weeks ago regarding the agency approving so few drugs last year.

  • Pfizer's Chantix Suffers Yet Another Blow From FDA Friday, 1 Feb 2008 | 4:53 PM ET

    Pfizer tried to get out in front of the psychiatric side-effect issues on its stop-smoking drug by adding information about behavioral changes, mood swings, thoughts of suicide, etc. to the label last month.

  • Medtronic Gets Approval for Drug-Coated Stent Friday, 1 Feb 2008 | 4:36 PM ET

    Medtronic on Friday received federal approval to sell its drug-coated stent, the first to hit the U.S. market since safety concerns sank their popularity two years ago.